The therapeutic effect of Poly-ADP-ribose polymerase (PARP) inhibitor has been demonstrated in ovarian cancer patients with BRCA mutation or homologous recombination deficiency (HRD). This evidence concerns the gene PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome.